<DOC>
	<DOCNO>NCT01470066</DOCNO>
	<brief_summary>Although interim 18F-fluoro-2-deoxy-D-glucose-positron emission tomography ( FDG-PET ) /computerized tomography ( CT ) scan emerge powerful prognostic tool predict treatment outcome Hodgkin 's lymphoma ( HL ) diffuse large B cell lymphoma ( DLBCL ) , positive predictive value ( PPV ) interim PET/CT scanning determine patient peripheral T cell lymphoma ( PTCL ) . The sequential interim PET/CT prospectively investigate determine whether provided additional prognostic information could positive predictable value treatment PTCL .</brief_summary>
	<brief_title>Clinical Usefulness Prognostic Significance Interim 18F-FDG PET/CT Treatment Peripheral T Cell Lymphomas</brief_title>
	<detailed_description>1 . Treatment protocol - Patients limited-stage ( stage I/II ) treat CHOP/CHOP-like chemotherapy [ cyclophosphamide 750 mg/m2 i.v . D1 , vincristine 1.4 mg/m2 i.v . D1 , doxorubicin 50 mg/m2 i.v . D1 , prednisolone 60 mg/m2 p.o . D1-5 ] standard dos every three week three four cycle CHOP/CHOP-like chemotherapy follow involved field radiation therapy ( IFRT , 30 Gy ) . Patients advanced-stage ( stage III/IV ) treat eight cycle primary chemotherapy patient great 65 year and/or frail general condition treat six cycle primary chemotherapy achieve complete response ( CR ) interim response . 2 . Response evaluation base three parameter visual , standard uptake value ( SUV ) -based metabolic tumor volume ( MTV ) -based assessment - We firstly classify patient five-point scale ( 5-PS ) interim PET/CT analysis base Deauville criteria12 : 1 , No uptake ; 2 , uptake ≤ mediastinum ; 3 , uptake &gt; mediastinum ≤ liver ; 4 , uptake moderately increase compare liver uptake site ; 5 , markedly increase uptake compare liver site new site or/and new site disease . Interim PET/CT image grade negative positive comparison initial PET/CT grade 1-3 consider negative grade 4-5 consider positive.19 This grade process independent size residual tumor . Secondly , classify patient quantitative analysis 18F-FDG uptake change base percentage SUVmax reduction initial interim PET/CT . On axial , coronal , sagittal coregistered PET/CT slice , simple circular region interest ( ROIs ) place cover lesion background . SUV measurement correct body weight accord follow standard formula : Mean ROI activity ( MBq/ml ) - [ Injected dose ( MBq ) /Body weight ( kg ) ] .20 For PET dataset , maximum SUV ( SUVmax ) define high SUV among hypermetabolic tumor focus . SUVmax reduction rate ( ΔSUVmax ) calculate follow : ΔSUVmax ( % ) = 100 x [ SUVmax ( initial ) - SUVmax ( interim ) ] /SUVmax ( initial ) If lesion disappear interim PET , ROI draw area interim PET baseline PET . We finally classify patient quantitative analysis metabolic volume change base percentage MTV reduction ( ΔMTV ) initial interim PET/CT . To define exact tumor margin around target lesion , SUV2.5 use follow previous report , mean tumor volume area PET/CT delineate circle encompass region SUV cutoff value 2.5.16,21 The MTV2.5 measure use AW Volume ShareTM workstation ( GE Healthcare ) fuse PET/CT images.17 AW Volume ShareTM allow automatic registration fusion two volumetric acquisition , come different acquisition modality . The active MTV2.5 measure 3-D manner select volume interest ( VOI ) axial image , size VOI manually regulate corresponding coronal sagittal image include entire active tumor VOI . The SUVmax sum tumor volume hypermetabolic tumor focus compute automatically program . The MTV2.5 reduction rate ( ΔMTV2.5 ) calculate formula SUVmax reduction rate . 3 . The response assessment interim PET/CT scan - assess base combination three parameter Deauville five-point scale ( 5-PS ) , reduction rate maximal standardize uptake value ( ΔSUVmax ) , reduction rate metabolic tumor volume ( ΔMTV2.5 ) PTCLs</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>1 . Age 18 year 2 . Histologically proven PTCLs except primary cutaneous/subcutaneous panniculitis 3 . ECOG performance status ≤ 2 4 . Patients available performed PET/CT diagnosis 5 . No severe concomitant disease 1 . Patients undergo PET/CT scan diagnosis 2 . Patients primary CNS lymphoma 3 . Patients HIV HTLV1 4 . Patients could receive primary chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>peripheral T cell lymphoma</keyword>
	<keyword>interim PET/CT</keyword>
	<keyword>prognosis</keyword>
	<keyword>Positron-emission tomography/Computerized tomography</keyword>
</DOC>